Poseida Therapeutics Stock Return On Equity

PSTX Stock

USD 9.31 0.02 0.21%

Poseida Therapeutics fundamentals help investors to digest information that contributes to Poseida Therapeutics' financial success or failures. It also enables traders to predict the movement of Poseida Stock. The fundamental analysis module provides a way to measure Poseida Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poseida Therapeutics stock.

		Last Reported	Projected for Next Year
	Return On Equity	(1.19)	(1.13)

Return On Equity is likely to rise to -1.13 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Poseida Therapeutics Company Return On Equity Analysis

Poseida Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Poseida Therapeutics Return On Equity

-0.58

Most of Poseida Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poseida Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Poseida Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Poseida Therapeutics is extremely important. It helps to project a fair market value of Poseida Stock properly, considering its historical fundamentals such as Return On Equity. Since Poseida Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Poseida Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Poseida Therapeutics' interrelated accounts and indicators.

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Long Term Debt	Good Will	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Intangible Assets	Deferred Long Term Liab	Capital Stock	Short Term Investments	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.83	0.2	0.61	0.83	0.84	0.72	0.85	0.94	0.69	0.13	0.72	-0.53	0.13	0.95	0.51	0.82	0.81	-0.57	0.71	0.88	0.79	0.61	0.65
Retained Earnings	-0.83		-0.52	-0.75	-0.85	-0.93	-0.8	-0.88	-0.7	-0.82	-0.07	-0.93	0.68	-0.58	-0.76	-0.78	-0.82	-0.84	0.84	-0.9	-0.94	-0.69	-0.79	-0.84
Accounts Payable	0.2	-0.52		0.05	0.4	0.4	0.79	0.43	0.19	0.17	-0.7	0.4	-0.18	0.53	0.23	0.6	0.37	0.6	-0.61	0.32	0.35	-0.16	0.12	0.21
Net Receivables	0.61	-0.75	0.05		0.56	0.79	0.33	0.56	0.45	0.7	0.53	0.84	-0.55	0.36	0.53	0.44	0.49	0.46	-0.45	0.9	0.83	0.68	0.98	0.94
Total Current Assets	0.83	-0.85	0.4	0.56		0.91	0.82	1.0	0.86	0.81	-0.13	0.87	-0.3	0.56	0.9	0.82	0.99	0.92	-0.82	0.6	0.88	0.81	0.6	0.58
Common Stock	0.84	-0.93	0.4	0.79	0.91		0.79	0.91	0.8	0.86	0.06	0.96	-0.42	0.49	0.86	0.8	0.86	0.84	-0.78	0.8	0.99	0.77	0.85	0.84
Property Plant Equipment	0.72	-0.8	0.79	0.33	0.82	0.79		0.83	0.75	0.52	-0.51	0.69	-0.25	0.42	0.77	0.74	0.8	0.91	-0.74	0.53	0.75	0.38	0.4	0.46
Total Assets	0.85	-0.88	0.43	0.56	1.0	0.91	0.83		0.86	0.81	-0.12	0.87	-0.34	0.55	0.9	0.82	0.99	0.93	-0.83	0.63	0.89	0.8	0.6	0.6
Total Stockholder Equity	0.94	-0.7	0.19	0.45	0.86	0.8	0.75	0.86		0.59	-0.08	0.64	-0.21	0.06	0.99	0.52	0.86	0.85	-0.52	0.51	0.8	0.76	0.47	0.46
Current Deferred Revenue	0.69	-0.82	0.17	0.7	0.81	0.86	0.52	0.81	0.59		0.31	0.89	-0.5	0.63	0.66	0.83	0.78	0.61	-0.83	0.67	0.84	0.86	0.78	0.79
Net Debt	0.13	-0.07	-0.7	0.53	-0.13	0.06	-0.51	-0.12	-0.08	0.31		0.14	-0.49	-0.11	-0.05	-0.21	-0.13	-0.32	0.14	0.37	0.14	0.43	0.46	0.44
Long Term Debt	0.72	-0.93	0.4	0.84	0.87	0.96	0.69	0.87	0.64	0.89	0.14		-0.47	0.66	0.72	0.84	0.82	0.77	-0.83	0.84	0.95	0.75	0.89	0.87
Good Will	-0.53	0.68	-0.18	-0.55	-0.3	-0.42	-0.25	-0.34	-0.21	-0.5	-0.49	-0.47		-0.32	-0.26	-0.27	-0.29	-0.28	0.44	-0.78	-0.51	-0.4	-0.52	-0.66
Total Liab	0.13	-0.58	0.53	0.36	0.56	0.49	0.42	0.55	0.06	0.63	-0.11	0.66	-0.32		0.15	0.77	0.55	0.43	-0.79	0.4	0.43	0.34	0.42	0.43
Net Invested Capital	0.95	-0.76	0.23	0.53	0.9	0.86	0.77	0.9	0.99	0.66	-0.05	0.72	-0.26	0.15		0.59	0.89	0.88	-0.59	0.58	0.86	0.79	0.55	0.54
Short Long Term Debt	0.51	-0.78	0.6	0.44	0.82	0.8	0.74	0.82	0.52	0.83	-0.21	0.84	-0.27	0.77	0.59		0.79	0.76	-0.97	0.51	0.73	0.56	0.54	0.55
Net Working Capital	0.82	-0.82	0.37	0.49	0.99	0.86	0.8	0.99	0.86	0.78	-0.13	0.82	-0.29	0.55	0.89	0.79		0.92	-0.81	0.55	0.83	0.81	0.53	0.51
Short Term Debt	0.81	-0.84	0.6	0.46	0.92	0.84	0.91	0.93	0.85	0.61	-0.32	0.77	-0.28	0.43	0.88	0.76	0.92		-0.79	0.61	0.82	0.6	0.47	0.48
Intangible Assets	-0.57	0.84	-0.61	-0.45	-0.82	-0.78	-0.74	-0.83	-0.52	-0.83	0.14	-0.83	0.44	-0.79	-0.59	-0.97	-0.81	-0.79		-0.6	-0.73	-0.58	-0.53	-0.56
Deferred Long Term Liab	0.71	-0.9	0.32	0.9	0.6	0.8	0.53	0.63	0.51	0.67	0.37	0.84	-0.78	0.4	0.58	0.51	0.55	0.61	-0.6		0.86	0.59	0.88	0.92
Capital Stock	0.88	-0.94	0.35	0.83	0.88	0.99	0.75	0.89	0.8	0.84	0.14	0.95	-0.51	0.43	0.86	0.73	0.83	0.82	-0.73	0.86		0.79	0.87	0.88
Short Term Investments	0.79	-0.69	-0.16	0.68	0.81	0.77	0.38	0.8	0.76	0.86	0.43	0.75	-0.4	0.34	0.79	0.56	0.81	0.6	-0.58	0.59	0.79		0.68	0.63
Long Term Debt Total	0.61	-0.79	0.12	0.98	0.6	0.85	0.4	0.6	0.47	0.78	0.46	0.89	-0.52	0.42	0.55	0.54	0.53	0.47	-0.53	0.88	0.87	0.68		0.97
Capital Surpluse	0.65	-0.84	0.21	0.94	0.58	0.84	0.46	0.6	0.46	0.79	0.44	0.87	-0.66	0.43	0.54	0.55	0.51	0.48	-0.56	0.92	0.88	0.63	0.97

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Poseida Therapeutics

Return On Equity Over Time

Poseida Other Stockholder Equity

Other Stockholder Equity

732.75 Million

At this time, Poseida Therapeutics' Other Stockholder Equity is fairly stable compared to the past year.

Based on the latest financial disclosure, Poseida Therapeutics has a Return On Equity of -0.5763. This is 97.6% lower than that of the Biotechnology sector and 98.42% lower than that of the Health Care industry. The return on equity for all United States stocks is 85.9% higher than that of the company.

Poseida Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poseida Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Poseida Therapeutics could also be used in its relative valuation, which is a method of valuing Poseida Therapeutics by comparing valuation metrics of similar companies.

Poseida Therapeutics is currently under evaluation in return on equity category among its peers.

Poseida Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Poseida Therapeutics from analyzing Poseida Therapeutics' financial statements. These drivers represent accounts that assess Poseida Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Poseida Therapeutics' important valuation drivers and their relationship over time.

		2019	2020	2021	2022	2023	2024 (projected)
Enterprise Value		551.3M	370.2M	278.3M	388.5M	344.0M	545.8M

Poseida Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Poseida Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Poseida Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Poseida Fundamentals

	Return On Equity	-0.58
	Return On Asset	-0.13
	Profit Margin	(0.40) %
	Operating Margin	0.28 %
	Current Valuation	759.29 M
	Shares Outstanding	97.47 M
	Shares Owned By Insiders	27.64 %
	Shares Owned By Institutions	58.48 %
	Number Of Shares Shorted	4.61 M
	Price To Earning	214.00 X
	Price To Book	10.40 X
	Price To Sales	6.03 X
	Revenue	64.7 M
	Gross Profit	(22.41 M)
	EBITDA	(109.04 M)
	Net Income	(123.43 M)
	Cash And Equivalents	142.56 M
	Cash Per Share	1.66 X
	Total Debt	85.42 M
	Debt To Equity	1.39 %
	Current Ratio	3.69 X
	Book Value Per Share	0.90 X
	Cash Flow From Operations	(92.17 M)
	Short Ratio	8.30 X
	Earnings Per Share	(0.63) X
	Price To Earnings To Growth	(0.63) X
	Target Price	9.5
	Number Of Employees	350
	Beta	0.54
	Market Capitalization	909.36 M
	Total Asset	273.88 M
	Retained Earnings	(594.29 M)
	Working Capital	155.16 M
	Current Asset	10.59 M
	Current Liabilities	5.1 M
	Net Asset	273.88 M

About Poseida Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Poseida Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poseida Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poseida Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC